A Phase 2 interventional study of Finerenone (BAY94-8862) and Placebo in Diabetic Nephropathies, sponsored by Bayer. Completed at 147 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-01.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing finerenone in Diabetic Nephropathies — 5 open to participants now, 5 under way, 1 of them phase 3. finerenone · Diabetic Nephropathies.
Among the 10 studies testing finerenone in Diabetic Nephropathies, this one is the 3rd largest by enrollment, is one of 2 that started in 2013, is one of 2 in phase 2, and was the 1st registered.
543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.
Browse Diabetic Nephropathies studies →5 of the 10 studies testing finerenone in Diabetic Nephropathies are open now, in 3 countries. Recruiting first, the newest first:
Huijie Zhang · Sites in China
Ages 18–70
Washington D.C. Veterans Affairs Medical Center · Sites in United States
Ages 20–90
Chittagong Medical College · Sites in Bangladesh
Ages 18+
Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Ages 18+
College of Physicians and Surgeons Pakistan
Ages 18+
By country, each count listing its studies:
finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 823 is above the median of 78 across 388 interventional studies indexed under Diabetic Nephropathies.
Median enrollment 108 across the 10 interventional studies. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 6 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 8 studies filed under Diabetic Nephropathies — fewer than ten, so there is no comparison to draw.
2 of the studies testing finerenone in Diabetic Nephropathies that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07598864Phase 3Chittagong Medical College"Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes" | 2027-05-01 |
| NCT07155694Washington D.C. Veterans Affairs Medical CenterRole of Finerenone in African American Veterans With Diabetic Kidney Disease | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing finerenone in Diabetic Nephropathies, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy. These treatment doses were compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with type 2 diabetes mellitus fulfilling at least 1 of the following criteria
Subjects with a clinical diagnosis of diabetic nephropathy (DN) based on at least 1 of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1.25 mg dose oral once daily for 90 days
Drug: Finerenone (BAY94-8862)
2.5 mg dose oral once daily for 90 days
Drug: Finerenone (BAY94-8862)
5 mg dose oral once daily for 90 days
Drug: Finerenone (BAY94-8862)
7.5 mg dose oral once daily for 90 days
Drug: Finerenone (BAY94-8862)
10 mg dose oral once daily for 90 days
Drug: Finerenone (BAY94-8862)
15 mg dose oral once daily for 90 days
Drug: Finerenone (BAY94-8862)
20 mg dose oral once daily for 90 days
Drug: Finerenone (BAY94-8862)
Placebo oral dose once daily for 90 days
Drug: Placebo
Ratio of UACR at Day 90 to UACR at Baseline
Albumin-to-creatinine ratio (UACR) is defined as gram of albumin per kilogram of creatinine. UACR was calculating the average of 3 first morning void samples taken on 3 consecutive days.
Time frame: Baseline and Day 90±2
Change From Baseline to Day 90 in Serum Potassium
Time frame: Baseline and Day 90±2
Change From Baseline to Day 90 in eGFR
An estimated glomerular filtration rate (eGFR) indicates the renal function. An eGFR was calculated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
Time frame: Baseline and Day 90±2
Change From Baseline to Day 90 in KDQOL-36 Domain Score (Effects of Kidney Disease)
The Kidney Disease QOL \[KDQOL\]-36 questionnaire is a specific measure of Health-Related Quality of Life (HRQoL) for chronic kidney disease (CKD) that includes effects and burden of kidney disease as well as physical and mental health scores. Index score ranges from 0 (severe problems in all items) to 100 (no problem in all items). "Effects of Kidney disease" subscore was analyzed.
Time frame: Baseline and Day 90±2
Change From Baseline to Day 90 in EQ-5D Scores (EQ5D - Visual Analog Scale)
EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L) questionnaires consist of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS was analyzed for this endpoint and it ranges from 0 (worst possible health state) to 100 (best possible health state).
Time frame: Baseline and Day 90±2
The study was conducted at 148 study centers in 23 countries, from 12 June 2013 (first participant, first visit) to 07 August 2014 (last participant, last visit). The randomization was stratified by region (Europe, North America, Asia, others \[Australia, Israel, and South Africa\]), and type of albuminuria at screening (very high or high albuminuria).
| Milestone | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo |
|---|---|---|---|---|---|---|---|---|
| Started | 96 | 92 | 100 | 98 | 98 | 125 | 120 | 94 |
| Participants received treatment | 96 | 92 | 100 | 97 | 98 | 125 | 119 | 94 |
| Completed | 90 | 87 | 90 | 91 | 90 | 114 | 112 | 90 |
| Not completed | 6 | 5 | 10 | 7 | 8 | 11 | 8 | 4 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 5 | 4 | 6 | 5 | 2 | 8 | 2 | 3 |
| Withdrew: Protocol violation | 1 | 1 | 1 | 0 | 3 | 2 | 1 | 1 |
| Withdrew: Non-compliance | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Logistical difficulties | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 2 | 1 | 1 | 3 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Albumin-to-creatinine ratio (UACR) is defined as gram of albumin per kilogram of creatinine. UACR was calculating the average of 3 first morning void samples taken on 3 consecutive days.
| Ratio | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo |
|---|---|---|---|---|---|---|---|---|
| Ratio of UACR at Day 90 to UACR at Baseline | 0.869 ± 0.772 | 0.89 ± 0.786 | 0.824 ± 0.73 | 0.739 ± 0.653 | 0.708 ± 0.627 | 0.63 ± 0.563 | 0.585 ± 0.523 | 0.938 ± 0.829 |
| millimole per liter | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Day 90 in Serum Potassium | 0.109 (0.030 to 0.187) | 0.123 (0.043 to 0.203) | 0.202 (0.122 to 0.282) | 0.127 (0.047 to 0.207) | 0.167 (0.087 to 0.248) | 0.238 (0.165 to 0.31) | 0.188 (0.116 to 0.259) | 0.002 (-0.077 to 0.081) |
An estimated glomerular filtration rate (eGFR) indicates the renal function. An eGFR was calculated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
| mL/min/1.73m^2 | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Day 90 in eGFR | -2.364 ± -4.311 | -3.189 ± -5.164 | -2.497 ± -4.475 | -3.378 ± -5.341 | -4.192 ± -6.181 | -3.806 ± -5.563 | -4.024 ± -5.792 | -1.578 ± -3.53 |
The Kidney Disease QOL \[KDQOL\]-36 questionnaire is a specific measure of Health-Related Quality of Life (HRQoL) for chronic kidney disease (CKD) that includes effects and burden of kidney disease as well as physical and mental health scores. Index score ranges from 0 (severe problems in all items) to 100 (no problem in all items). "Effects of Kidney disease" subscore was analyzed.
| scores on a scale | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Day 90 in KDQOL-36 Domain Score (Effects of Kidney Disease) | -2.116 ± -4.521 | 0.104 ± -2.369 | -1.229 ± -3.643 | -1.185 ± -3.597 | -2.596 ± -5.049 | 0.112 ± -2.054 | 0.058 ± -2.146 | 0.747 ± -1.684 |
EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L) questionnaires consist of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS was analyzed for this endpoint and it ranges from 0 (worst possible health state) to 100 (best possible health state).
| scores on a scale | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Day 90 in EQ-5D Scores (EQ5D - Visual Analog Scale) | 1.381 ± -1.22 | 3.888 ± 1.208 | 3.124 ± 0.494 | 2.851 ± 0.241 | 2.698 ± 0.026 | 2.743 ± 0.394 | 1.914 ± -0.465 | 4.425 ± 1.794 |
Collected over Up to approximately 93 days after the start of study drug. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Finerenone (BAY94-8862) (1.25 mg) | 0/96 (0%) | 5/96 (5.2%) | 14/96 (14.6%) |
| Finerenone (BAY94-8862)(2.5 mg) | 0/92 (0%) | 3/92 (3.3%) | 7/92 (7.6%) |
| Finerenone (BAY94-8862)(5 mg) | 0/100 (0%) | 7/100 (7%) | 13/100 (13%) |
| Finerenone (BAY94-8862)(7.5 mg) | 0/97 (0%) | 8/97 (8.2%) | 11/97 (11.3%) |
| Finerenone (BAY94-8862)(10 mg) | 0/98 (0%) | 2/98 (2%) | 10/98 (10.2%) |
| Finerenone (BAY94-8862)(15 mg) | 1/125 (0.8%) | 6/125 (4.8%) | 11/125 (8.8%) |
| Finerenone (BAY94-8862)(20 mg) | 0/119 (0%) | 4/119 (3.4%) | 12/119 (10.1%) |
| Placebo | 1/94 (1.1%) | 3/94 (3.2%) | 8/94 (8.5%) |
| Event | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862)(2.5 mg) | Finerenone (BAY94-8862)(5 mg) | Finerenone (BAY94-8862)(7.5 mg) | Finerenone (BAY94-8862)(10 mg) | Finerenone (BAY94-8862)(15 mg) | Finerenone (BAY94-8862)(20 mg) | Placebo |
|---|---|---|---|---|---|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 2/96 | 0/92 | 1/100 | 1/97 | 0/98 | 2/125 | 2/119 | 0/94 |
| Blood potassium increasedInvestigations | 0/96 | 1/92 | 0/100 | 1/97 | 0/98 | 2/125 | 1/119 | 0/94 |
| Non-cardiac chest painGeneral disorders | 0/96 | 1/92 | 0/100 | 0/97 | 0/98 | 0/125 | 0/119 | 0/94 |
| Pancreatic enzymes increasedInvestigations | 0/96 | 1/92 | 0/100 | 0/97 | 0/98 | 0/125 | 0/119 | 0/94 |
| Local swellingGeneral disorders | 0/96 | 0/92 | 0/100 | 0/97 | 0/98 | 0/125 | 0/119 | 1/94 |
| Cerebrovascular accidentNervous system disorders | 0/96 | 0/92 | 0/100 | 1/97 | 0/98 | 0/125 | 0/119 | 1/94 |
| Ischaemic strokeNervous system disorders | 0/96 | 0/92 | 0/100 | 0/97 | 0/98 | 0/125 | 0/119 | 1/94 |
| Hypertensive crisisVascular disorders | 0/96 | 0/92 | 0/100 | 0/97 | 0/98 | 0/125 | 0/119 | 1/94 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/96 | 0/92 | 0/100 | 0/97 | 0/98 | 0/125 | 0/119 | 0/94 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/96 | 0/92 | 0/100 | 1/97 | 0/98 | 0/125 | 0/119 | 0/94 |
| Event | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862)(2.5 mg) | Finerenone (BAY94-8862)(5 mg) | Finerenone (BAY94-8862)(7.5 mg) | Finerenone (BAY94-8862)(10 mg) | Finerenone (BAY94-8862)(15 mg) | Finerenone (BAY94-8862)(20 mg) | Placebo |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 7/96 | 4/92 | 8/100 | 9/97 | 5/98 | 4/125 | 8/119 | 5/94 |
| DizzinessNervous system disorders | 6/96 | 1/92 | 3/100 | 1/97 | 3/98 | 5/125 | 1/119 | 2/94 |
| DiarrhoeaGastrointestinal disorders | 5/96 | 2/92 | 4/100 | 2/97 | 2/98 | 3/125 | 5/119 | 2/94 |
Safety analysis set (SAF): all randomized subjects who took at least one dose of study drug and with data after beginning of treatment.
| Age, Continuous(years) | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 64.91 ± 9.57 | 64.86 ± 9.09 | 63.31 ± 8.79 | 63.73 ± 10.04 | 64.94 ± 9.62 | 63.95 ± 8.34 | 64.70 ± 9.26 | 63.26 ± 8.68 | 64.21 ± 9.15 |
| Sex: Female, Male(Participants) | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 18 | 14 | 29 | 18 | 21 | 27 | 30 | 25 | 182 |
| Male | 78 | 78 | 71 | 79 | 77 | 98 | 89 | 69 | 639 |
| Baseline UACR(g/kg) | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 412.02 ± 507.51 | 471.01 ± 784.84 | 402.04 ± 535.44 | 405.14 ± 702.63 | 441.16 ± 571.27 | 450.12 ± 657.04 | 379.28 ± 457.33 | 377.28 ± 542.27 | 417.16 ± 599.12 |
| Baseline potassium(mmol/L) | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 4.323 ± 0.425 | 4.297 ± 0.426 | 4.314 ± 0.325 | 4.311 ± 0.435 | 4.297 ± 0.420 | 4.288 ± 0.459 | 4.294 ± 0.439 | 4.254 ± 0.479 | 4.297 ± 0.427 |
| Baseline eGFR(mL/min/1.73m^2) | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 66.113 ± 21.923 | 67.425 ± 20.164 | 67.080 ± 22.205 | 67.497 ± 21.917 | 67.042 ± 20.857 | 67.455 ± 23.646 | 66.039 ± 22.205 | 72.213 ± 20.434 | 67.544 ± 21.772 |
| Baseline KDQOL-36 domain score (Effects of Kidney Disease)(Scores on a scale) | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 90.78 ± 10.28 | 92.53 ± 9.57 | 91.78 ± 12.55 | 92.99 ± 11.04 | 88.71 ± 16.50 | 90.45 ± 14.39 | 89.10 ± 17.45 | 81.45 ± 20.42 | 90.57 ± 13.69 |
| Baseline EQ-5D scores (EQ5D - Visual Analog Scale)(Score on a scale) | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 71.76 ± 16.39 | 72.79 ± 14.81 | 73.01 ± 16.21 | 74.49 ± 15.92 | 73.89 ± 16.47 | 73.19 ± 16.11 | 71.36 ± 17.49 | 70.05 ± 17.69 | 72.56 ± 16.42 |
Showing the first 100 of 147 sites across 23 countries. Choose a country and city above to see the rest.
Ran from Jun 2013 to primary completion in Jul 2014, 12 months.
Results were first posted in May 2021, 6 years 9 months after primary completion. A results delay was requested in Jun 2015.
Of 32 industry-sponsored phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 12 months is below that.
Counting every sponsor, half of 52 studies reached it within 21 months; a quarter within 13 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Finerenone